To include your compound in the COVID-19 Resource Center, submit it here.

Lilly and Incyte delay NDA resubmission for Olumiant in RA

Eli Lilly and Co. (NYSE:LLY) said it would delay beyond 2017 its plans to resubmit

Read the full 159 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE